
ADMdx offers advanced brain image analysis for dementia diagnosis, aiding pharmaceutical trials and patient care.
ADM Diagnostics, founded with a mission to enhance the diagnosis and treatment of brain disorders, specializes in advanced brain image analysis. The company focuses on Alzheimer's disease and other forms of dementia, providing pharmaceutical companies with critical data to improve clinical trial outcomes. ADMdx offers comprehensive CNS imaging study services, including structural MRI, amyloid PET, tau PET, FDG PET, ASL, fMRI BOLD, and DTI. They are also developing diagnostic products for early and accurate disease detection.
Notable figures affiliated with ADMdx include its expert team of neuroscientists and imaging specialists. The company has achieved significant milestones, such as receiving 510(k) FDA clearance for its CorInsights® MRI product. This clearance underscores ADMdx's impact on the field by providing reliable tools for clinical trials and patient care. Their work supports pharmaceutical advancements and contributes to the broader understanding and treatment of neurodegenerative diseases.

Diamir
diamirbio.com

Darmiyan
darmiyan.com

Amydis
amydis.com

Synaps Dx
synapsdx.com

NeuroVision Imaging
neurovision.com

Digital Diagnostics

Alzeca Biosciences
alzeca.com

Ocular Diagnostics

Decision Sciences Medical

Durin Technologies

C2N Diagnostics
c2n.com

Empowered Diagnostics

Jan Medical
janmedical.com

Haystack Dx

Smart Diagnostics Systems
Companies similar to ADM Diagnostics include Diamir, Darmiyan, Amydis and Synaps Dx.
ADM Diagnostics was founded in 2010.
ADM Diagnostics' headquarters is located in Northbrook, IL, US.
ADM Diagnostics' most recent funding round was for $2M (USD) in September 2022.
As of Sep 27, 2022, ADM Diagnostics has raised a total of $2.9M (USD).
ADM Diagnostics has 30 employees as of Feb 5, 2024.